


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 29. (Cancelled).

30. (Previously presented) A method of treating diffuse large B-cell lymphoma in a subject, said method comprising the step of orally administering to the subject a total daily dose of up to about 600 mg of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:



or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, wherein administration of SAHA is effective to treat diffuse large B-cell lymphoma in said subject.

31. (Cancelled).

32. (Previously presented) The method of claim 30, wherein said composition is contained within a gelatin capsule.

33. (Original) The method of claim 32, wherein said carrier or diluent is microcrystalline cellulose.

34. (Original) The method of claim 33, further comprising sodium croscarmellose as a disintegrating agent.

35. (Original) The method of claim 34, further comprising magnesium stearate as a lubricant.

36. (Cancelled).

37. (Previously presented) The method of claim 30, wherein said composition is administered once-daily, twice-daily or three times-daily.

38. (Original) The method of claim 37, wherein said composition is administered once daily at a dose of about 200-600 mg.

39. (Previously presented) The method of claim 37, wherein said composition is administered twice daily at a dose of about 150 mg, 200 mg, or 300 mg.

40. (Previously presented) The method of claim 37, wherein said composition is administered twice daily at a dose of about 150 mg, 200 mg, or 300 mg intermittently.

41. (Original) The method of claim 40, wherein said composition is administered three to five days per week.

42. (Original) The method of claim 40, wherein said composition is administered three days a week.


43. (Original) The method of claim 42, wherein said composition is administered at a dose of about 200 mg.

44. (Original) The method of claim 42, wherein said composition is administered at a dose of about 300 mg.

45. (Original) The method of claim 42, wherein said composition is administered at a dose of about 400 mg.

46. (Previously presented) The method of claim 37, wherein said composition is administered three times daily at a dose of about 100 mg or 150 mg.

47. (Previously presented) A method of treating diffuse large B-cell lymphoma in a subject, said method comprising the step of orally administering to the subject a total daily dose of up to about 800 mg of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:



or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, wherein administration of SAHA is effective to treat diffuse large B-cell lymphoma in said subject.

48. (Cancelled).

49. (Previously presented) The method of claim 47, wherein said composition is contained within a gelatin capsule.

50. (Original) The method of claim 49, wherein said carrier or diluent is microcrystalline cellulose.

51. (Original) The method of claim 50, further comprising sodium croscarmellose as a disintegrating agent.

52. (Original) The method of claim 51, further comprising magnesium stearate as a lubricant.

53. (Previously presented) The method of claim 47, wherein said composition is administered once-daily, twice-daily or three times-daily.

54. (Original) The method of claim 53, wherein said composition is administered once daily at a dose of about 200-600 mg.

55. (Original) The method of claim 53, wherein said composition is administered twice daily at a dose of about 200-400 mg.

56. (Original) The method of claim 53, wherein said composition is administered twice daily at a dose of about 200-400 mg intermittently.

57. (Original) The method of claim 56, wherein said composition is administered three to five days per week.

58. (Original) The method of claim 56, wherein said composition is administered three days a week.

59. (Original) The method of claim 58, wherein said composition is administered at a dose of about 200 mg.

60. (Original) The method of claim 58, wherein said composition is administered at a dose of about 300 mg.

61. (Original) The method of claim 58, wherein said composition is administered at a dose of about 400 mg.

62. (Original) The method of claim 53, wherein said composition is administered three times daily at a dose of about 100-250 mg.

63. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 400 mg continuously.

64. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 600 mg continuously.

65. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 400 mg intermittently.

66. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 600 mg intermittently.

67. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 400 mg for 14 consecutive days in a 21 day schedule.

68. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 600 mg for 14 consecutive days in a 21 day schedule.

69. (Currently amended) The method of any one of claims 30, 32-35, 37-47, and 49-68, wherein SAHA is the active ingredient in said composition administered.